# A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis

> **NCT07420257** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.** · enrollment: 212 (estimated)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **BIOLOGICAL:** CM326 injection
- **DRUG:** Placebo of CM326

## Key facts

- **NCT ID:** NCT07420257
- **Lead sponsor:** CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-28
- **Primary completion:** 2028-10-30
- **Final completion:** 2028-10-30
- **Target enrollment:** 212 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07420257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07420257, "A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07420257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*